Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1995-05-23
1998-06-30
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
4241331, 4241341, 4241421, 4241431, 4241551, 4241561, 4241741, 4241831, 53038822, 5303673, 5303877, 5303888, A61K 39395, C07K 1630, C07K 1646, C12P 2108
Patent
active
057729972
ABSTRACT:
A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treatment tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4906646 (1990-03-01), Honn et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4957735 (1990-09-01), Huang
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5108934 (1992-04-01), Rokugawa et al.
patent: 5288477 (1994-02-01), Bacus
patent: 5401638 (1995-03-01), Carney et al.
patent: 5470571 (1995-11-01), Herlyn et al.
Aboud-Pirak et al., "Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice" Journal of the National Cancer Institute 80(20):605-1611 (Dec. 21, 1988).
Ballet et al., "Evaluation of a Nude Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agenst" J. Natl. Canc. Inst 63(5):1185-1188 (1979).
Bernards et al., "Effective Tumor Immunotherapy Directed Against an Oncogene-encoded Product Using a Vaccinia Virus Vector" Proc. Natl. Acad. Sci. USA 84:6854-6858 (Oct. 1987).
Bucholtz, J.D., "Radiolabeled Antibody Therapy" Semin. Oncol. Nurs. (abstract only) 3(1):67-73 (1987).
Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" Oncogene 2:273-277 (1988).
Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" Cancer Research 51:4575-4580 (Sep. 1, 1991).
Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" Jpn J. Cancer Res. 80:10-14 (Jan. 1989).
Park et al., "Development of anti-p185.sup.HER2 Immunoliposomes for Cancer Therapy" Proc. Natl. Acad. Sci. USA 92:1327-1331 (Feb. 1995).
Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" Nature 312:724-729 (1984).
Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2" Molecular Immunology 28(8):915-917 (1991).
Arteaga et al., "Antibodies Against p185/HER2 Enhance Etoposide-Induced Cytotoxicity Against Human Breast Carcinoma Cells" Proceedings of ASCO-29th Annual Meeting (Abstract #101), Orlando, FL 12:75 (1993).
Bargmann et al., "Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185 " Cell 45:649-659 (Jun. 6, 1986).
Baselga et al., "Anti Her2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" Proceedings of ASCO-13th Annual Meeting (Abstract #53), Dallas, TX 13:63 (1994).
Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185/HER2 Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer" J. Clin. Oncol. 14(3):737-744 (1996).
Baselga et al., "Receptor Blockade With Monoclonal Antibodies as Anti-Cancer Therapy" Pharmac. Ther. 64:127-154 (1994).
Beguinot et al., "Down-Regulation of the Epidermal Growth Factor Receptor in KB Cells is Due to Receptor Internalization and Subsequent Degradation in Lysozymes" Proc. Natl. Acad. Sci. USA 81(8):2384-2388 (1984).
De Santes et al., "Radiolabeled Antibody Targeting of the HER-2
eu Oncoprotein-1" Cancer Research 52:1916-1923 (1992).
Lyall et al., "EGF Induces Receptor Down-regulation with No Receptor Recycling in KB Cells" J. Cell Physiol 122(1):166-170 (1985).
Pegram et al., "Monoclonal Antibody to HER-2
eu Gene Product Potentiates Cytotoxicity of Carboplatin and Doxorubicin in Human Breast Tumor Cells" Proceedings of the American Assoc. for Cancer Research (Abstract # 2639-83rd Annual Meeting), San Diego, CA 33:442 (1992).
Pegram et al., "Phase II Study of Intravenous Recombinant Humanized Anti-p185 Monoclonal" Proceedings of the ASCO-31st Annual Meeting (Abstract #124), Los Angeles, CA 14:106. (1995).
Pietras et al., "Antibody to HER-2
eu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" Oncogene 9:1829-1838 (1994).
Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" J. Clin. Immunol. 11(3):117-127 (1991).
Taetle et al., "Effects of Anti-Epidermal Growth Factor (EGF) Receptor Antibodies and an Anti EGF Receptor Rocombinant-ricin A Chain Immunoconjugate on Growth of Human Cells" J. Natl. Cancer Institute 80(13):1053-1059 (1988).
Kipps et al., "Schemata for the production of monoclonal antibody-producing hybridomas" Handbook of Experimental Immunology, Herzenberg et al. (eds.), Blackwell Sci., Chapter 108, pp. 108.1-108.9 (1986).
Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185.sup.erbB2 " Science 249:1552-1555 (1990).
Mansi et al., "In vivo Evaluation of an Anti-Melanoma Antibody, F(ab').sub.2, Labelled with TC-99m" Oncogenes to Tumor Antigens, Geraldo et al., eds., Elsevier Sci. Publ. (1985).
Masui et al., "Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes" Cancer Research 46:5592-5598 (1986).
McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" Oncogene 4:543-548 (1989).
Morrison, "Transfectomas Provide Novel Chimeric Antibodies" Science 229:1202-1207 (1985).
Muller et al., "Single-Step Induction of Mammary Adenocarcinoma in Transgenic Mice Bearing the Activated c-neu Oncogene" Cell 54:105-115 (1988).
Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185.sup.neu " Methods in Enzymology 198:277-290 (1991).
Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas" Cell 28:865-871 (1982).
Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" J. Cellular Biochem. 35(4):315-320 (1987).
Rodeck et al., "Tumor Growth Modulation by a Monoclonal Antibody to the Epidermal Growth Factor Receptor: Immunologically Mediated and Effector Cell-independent Effects" Cancer Research 47(14):3692-3696 (1987).
Rosenthal et al., "Expression in Rat Fibroblasts of a Human Transforming Growth Factor-.alpha. cDNA Results in Transformation" Cell 46:301-309 (1986).
Sato et al., "Biological Effects in Vitro of Monoclonal Antibodies to Human Epidermal Growth Factor Receptors" Mol. Biol. Med. 1:511-529 (1983).
Schechter et al., "The neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor" Science 229:976-978 (1985).
Schlom et al., "Basic Principles and Applications of Monoclonal Antibodies on the Management of Carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture" Cancer Research 46:3225-3238 (1986).
Semba et al., "A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" Proc. Natl. Acad. Sci. USA 82:6497-6501 (1985).
Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene" Science 235:177-182 (1987).
Sobol et al., "Epidermal Growth Factor Receptor Expression in Human Lung Carcinomas Defined by a Monoclonal Antibody" J. Natl. Cancer Institute 79(3):403-407 (1987).
Sugarman et al., "Effects of Growth Factors on the Antiproliferative Activity of Tumor Necrosis Factor" Cancer Research 47:780-786 (1987).
Sugarman et al., "Recombi
Fendly Brian M.
Hudziak Robert M.
Shepard H. Michael
Ullrich Axel
Bansal Geetha P.
Feisee Lila
Genentech Inc.
Lee Wendy M.
LandOfFree
Monoclonal antibodies directed to the HER2 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies directed to the HER2 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies directed to the HER2 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1856188